Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

08:16
10/10/16
10/10
08:16
10/10/16
08:16

Mylan settlement does not end EpiPen issue, says Wells Fargo

In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.

  • 09

    Nov

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
RAJA
10/10/16
UPGRADE
RAJA
Strong Buy
Mylan upgraded to Strong Buy from Market Perform at Raymond James
10/10/16
UBSW
10/10/16
NO CHANGE
Target $60
UBSW
Buy
UBS remains constructive on Mylan despite governance controversy
UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman cited the company's ability to execute, its surprise announcement of a EpiPen Medicaid lawsuit settlement and its updated guidance, which was better than feared. Goodman reiterated his Buy rating and lowered his price target to $60 from $66 on Mylan shares.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.